Loading data for THNR — first visit, this takes a few seconds.

Alert

Alerta

Amplify Weight Loss Drug ... (THNR)

NYSEArca: THNR · Precio en tiempo real · USD

27.25

+0.79 (2.99%)

Al cierre: Aug 20, 2026, 7:59 PM

27.25

+0.00%

Fuera de horario: 6:16 PM

2.99% (1D)

No hay datos disponibles

Precio de compra	11.07
Capitalización de mercado	n/a
AUM	5.07M
NAV	26.46
Beta	n/a
EPS (ttm)	n/a
Relación PE (ttm)	19.73
Acciones en circulación	n/a
Fecha de inicio	May 20, 2024

Precio de venta	43.77
Volumen	6,678
Volumen medio (20D)	2,137
Abierto	27.14
Cierre anterior	26.46
Rango del día	27.14 - 27.53
Rango de 52 semanas	22.63 - 27.55
Participaciones	n/a
Relación de gastos	0.59%

Acerca de THNR

The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Clase de activo Equity

Símbolo bursátil THNR

Fecha de inicio May 20, 2024

Proveedor Amplify Etfs

Sitio web Página de inicio del fondo

Intercambio NYSEArca

Sectores principales

Sector	% en peso
Healthcare	100.00%

Ver todos los sectores

Las 10 principales participaciones 61.60% de activos

Nombre	Símbolo	Peso
Novo Nordisk As Adr	NVO	9.70%
Eli Lilly And Co	LLY	8.92%
Regeneron Pharmaceut...	REGN	6.03%
Cspc Pharmaceutical ...	1093.HK	5.52%
Arrowhead Pharmaceut...	ARWR	5.34%
Innovent Biologics I...	1801.HK	5.34%
Amgen Inc	AMGN	5.25%
Abbvie Inc	ABBV	5.24%
Roche Holding Ag Ord...	ROP.SW	5.20%
Merck & Co Inc	MRK	5.06%

Ver más participaciones

Dividendos Rendimiento de dividendos 1.52%

Ex-Dividendo	Cantidad	Fecha de pago
Dec 30, 2025	$0.4130	n/a
Dec 30, 2024	$0.2200	n/a

Historial completo de dividendos

Noticias

1 mes hace · Zacks

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

2 meses hace · Zacks

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

3 meses hace · Zacks

GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

4 meses hace · MarketBeat

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

5 meses hace · Zacks

FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs

Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.

Página 1 de 2